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Background
Disease recurrence in patients with acute myeloid leukemia may be partially explained by the
escape of leukemic blasts from CD4+ T-cell recognition. The current study investigates the role
of aberrant HLA class II antigen presentation on leukemic blasts by determining both the clin-
ical and functional impact of the class II-associated invariant chain peptide (CLIP).
Design and Methods
The levels of expression of CLIP and HLA-DR on blood and bone marrow samples from 207
patients with acute myeloid leukemia were correlated with clinical outcome. Irradiated CLIP–
and CLIP+ leukemic blasts were compared for their ability to induce CD4+ T cells during mixed
leukocyte reactions. To discriminate between these blasts, we down-modulated CLIP expres-
sion on myeloid leukemic cell lines by RNA interference of the invariant chain, a chaperone
protein critically involved in HLA-DR processing, and performed flow cytometric sorting for
their isolation from primary acute myeloid leukemia samples. 
Results
We found that patients with leukemic blasts characterized by a high amount of HLA-DR occu-
pied by CLIP (relative amount of CLIP) had a significantly shortened disease-free survival. The
clear reductions in amount of HLA-DR occupied by CLIP on blasts of the THP-1 and Kasumi-
1 myeloid leukemic cell lines after treatment with invariant chain short interfering RNA result-
ed in enhanced rates of allogeneic CD4+ T-cell proliferation. Similar findings were obtained in
an autologous setting, in which there were strong increases in proliferation of remission CD4+
T cells stimulated with CLIP–-sorted leukemic blasts from HLA-DR+ acute myeloid leukemia
patients, in contrast to CLIP+-sorted leukemic blasts from the same patients.
Conclusions
These data highlight the relevance of CLIP expression on leukemic blasts and the potential of
CLIP as a target for immunomodulatory strategies to enhance HLA class II antigen presentation
and CD4+ T-cell reactivity in acute myeloid leukemia.
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Introduction
Although intensive chemotherapy induces complete
remission in 70-80% of younger and 40-60% of elderly
patients with acute myeloid leukemia (AML), relapses still
occur in the majority of cases.1 It is hypothesized that
leukemic blasts, which survive induction and consolidation
treatment, have acquired a non-immunogenic phenotype
during the process of immune editing,2 resulting in the out-
growth of minimal residual disease. Manipulation of this
immune escape phenomenon could, therefore, have impor-
tant implications for the development of additional
immunotherapeutic strategies aimed at eradicating minimal
residual disease in AML patients.3 The immunotherapeutic
strategies most commonly used, including allogeneic
hematopoietic stem cell transplantation and donor lympho-
cyte infusions, are based on the generation of specific CD8+
cytotoxic lymphocyte (CTL) responses against leukemic
blasts in vivo.4,5 In order to induce an effective and long-lasting
anti-leukemic T-cell response, however, CD4+ T cells are nec-
essary to provide help to CTL upon activation by antigen-
presenting cells (APC).6,7 Also, in mice suffering from myeloid
leukemia, CTL-mediated graft-versus-leukemia responses fol-
lowing delayed donor lymphocyte infusion were totally
dependent on CD4+ T-cell help and were significantly
reduced when donor APC lacked MHC class II expression.8
Since tumor-specific activation of CD4+ T cells relies on
optimal presentation of tumor antigens by HLA class II mol-
ecules, the HLA class II presentation pathway in APC is like-
ly to play an important role in anti-tumor immunity. During
HLA class II synthesis, class II α and β chains dimerize in the
endoplasmic reticulum and associate with the invariant chain
(Ii) to form a nonameric complex. This interaction with Ii
contributes to proper folding and prevents premature peptide
loading of the HLA class II molecule.9,10 Furthermore, Ii plays
an important role in HLA class II trafficking from the endo-
plasmic reticulum to lysosomal antigen-loading compart-
ments called MIIC (MHC class II antigen-loading compart-
ments).11 During transport from the endoplasmic reticulum to
the MIIC, Ii is proteolytically cleaved and a small peptide
remnant, called the class II-associated invariant chain peptide
(CLIP), remains associated with the antigen-binding groove.12
For binding of exogenously derived antigenic peptides,
which are processed in the endosomal/lysosomal pathway,
CLIP has to be released from the antigen-binding groove by
a specialized HLA-like chaperone, termed HLA-DM.13 In B
cells, another molecule residing in the MIIC, HLA-DO, is
able to down-regulate the catalytic function of HLA-DM,
resulting in limited presentation of exogenous antigens at the
plasma membrane.14
In tumors lacking HLA class II expression, tumor-specific
CD4+ T-cell activation can only be induced by professional
APC that are loaded with tumor antigens.15 We and others
demonstrated in mice that tumor cells transfected with HLA
class II genes are able to present tumor antigens at the plasma
membrane and can induce strong CD4+ T-cell responses.16,17
Interestingly, these and other studies further revealed that Ii
expression in HLA class II-transfected tumor cells is negative-
ly involved in activating tumor-reactive CD4+ T cells.18,19 This
indicates that the absence of Ii in HLA class II-expressing
tumor cells contributes to efficient HLA class II-mediated
presentation of endogenously synthesized tumor peptides,
leading to activation of tumor-specific CD4+ T cells.
In the case of AML, leukemic blasts have an intrinsic prop-
erty of expressing both HLA class II and co-stimulatory mol-
ecules at the plasma membrane.20,21 For this reason, it could be
hypothesized that leukemic blasts expressing Ii intracellular-
ly, as well as HLA-DR and CLIP at the plasma membrane, are
able to escape immune surveillance by circumventing
leukemia-specific CD4+ T-cell recognition. In line with this
hypothesis, we previously showed that a high expression of
CLIP on leukemic blasts of AML patients predicts a shortened
disease-free survival.22 In the current study, we expanded our
cohort of newly diagnosed AML patients and confirmed that
a high relative amount of CLIP (the relative amount of HLA-
DR occupied by CLIP) on leukemic blasts is significantly cor-
related with a poor clinical outcome. In addition, we report
that a low relative amount of CLIP on leukemic blasts of
HLA-DR+ myeloid cell lines and from AML patients clearly
improves CD4+ T-cell recognition, indicating that CLIP down-
modulation is a promising immunomodulatory strategy to
optimize HLA class II antigen presentation and tumor
immunogenicity in AML patients. 
Design and Methods
Patients’ samples
Blood and bone marrow samples were collected, in accordance
with the declaration of Helsinki, from 207 patients with previously
untreated AML between 1992 and 2007. Informed consent was
obtained from all patients for the research use of their specimens,
with approval of the institutional review board. The diagnosis of
AML and its subtypes was made according to the French-American-
British (FAB) criteria.23 Patients with acute promyelocytic leukemia
(FAB-M3), whose leukemic blasts lacked HLA-DR expression, were
excluded. All patients received remission induction and consolida-
tion therapy according to the HOVON (Dutch-Belgian Hematology-
Oncology Cooperative Group) protocols, available at www.hovon.nl.
Cytogenetic risk group was defined as favorable [t(8;21) or inver-
sion(16)], standard (neither favorable nor adverse), or adverse [com-
plex karyotype, -5 or -7, deletion(5q), abnormality 3q or 11q23].1
Overall survival was defined as the period from inclusion to death or
last date of follow-up. Disease-free survival was defined as the peri-
od between achievement of complete remission and the moment of
relapse or the last date of follow-up in non-relapsed patients.
Bone marrow and peripheral blood mononuclear cells, with-
drawn before the start of therapy, were collected through density-
gradient centrifugation (Ficoll-PaquePLUS; Amersham Biosciences,
Freiburg, Germany). Samples were analyzed by flow cytometry
immediately or cryopreserved in liquid nitrogen until analysis. 
Cell lines and cell cultures
Human myeloid leukemic cell lines HL-60 (FAB-M2), THP-1 (FAB-
M5), U-937 (FAB-M5), Kasumi-1 (FAB-M2), ME-1 (FAB-M4eo) and
KG-1 (FAB-M0/1) were purchased from the American Type Culture
Collection (ATTC) and frozen in aliquots at low cell passage. HL-60,
THP-1 and U-937 cell lines were maintained in RPMI 1640 medium
(Gibco, Paisley, UK) supplemented with 1% L-glutamine and 10%
heat-inactivated fetal bovine serum (FBS; Greiner, Alphen a/d Rijn,
The Netherlands) at a cell density of 5×105 cells/mL. Similar culture
conditions were used for both the Kasumi-1 and ME-1 cell lines,
except that in these cases the medium contained 15% and 20% FBS,
respectively. The KG-1 cell line was cultured at a density of 3×105
cells/mL in Iscove’s modified Dulbecco’s medium (Gibco) supple-
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mented with 20% FBS, 1% L-glutamine (Gibco), 25 mM Hepes
(Sigma-Aldrich, St Louis, MO, USA) and 50 µM 2-ME (Gibco). Cells
were incubated at 37°C in a humidified atmosphere containing 5%
CO2 and culture medium was refreshed every 2-3 days. 
Antibodies and immunofluorescence staining
The following mouse monoclonal antibodies were used: phyco-
erythrin (PE)-labeled cerCLIP.1 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-HLA-DM (BD PharMingen, San Diego, CA,
USA), CD27 and IgG1 isotype control (BD, San Jose, CA, USA); flu-
orescein isothiocyanate (FITC)-labeled anti-HLA-DR (L243 isotype;
BD), anti-HLA-DO (BD PharMingen), CD45RA (Sanquin,
Amsterdam, The Netherlands), CD45RO (Dako, Glostrup,
Denmark), CD4 (BD), IgG2a (Dako) and IgG2b (BD PharMingen)
isotype controls; peridin chlorophyll (PerCP)-labeled CD45, CD8
and IgG1 isotype control (BD); allophycocyanin (APC)-labeled CD3
and IgG1 isotype control (BD); and 7-amino-actinomycin D (7AAD;
Via-Probe, BD). PIN1.1 antibody (anti-Ii) was kindly provided by
Peter Cresswell (Howard Hughes Medical Institute, Yale University
School of Medicine, New Haven, CT, USA).24 Anti-HLA-DR block-
ing antibodies L243 were prepared from supernatants of the HB-55
hybridoma (ATCC). Immunofluoresence staining was performed as
indicated in the Online Supplementary Appendix.
Cell lysate preparation and western blotting
For western blot analysis, 10×106 myeloid leukemic blasts were
washed three times with sterile phosphate-buffered saline (PBS)
(pH 7.4). Cell lysates were prepared by snap-freezing the samples
in liquid nitrogen and incubating them for 45 min in 250 µL ice-cold
lysis buffer, which consisted of PBS supplemented with 1% Ipegal
and 15% protease inhibitor cocktail (Complete; 1 tablet per 7.5 mL
H2O; Boehringer Mannheim Biochemica, Mannheim, Germany).
After centrifugation in an Eppendorf micro-centrifuge (5 min,
10,000 rpm), the protein content of the supernatant was deter-
mined by the Bio-Rad protein assay (Biorad Laboratories, Hercules,
CA, USA). Then, proteins from 10 µg of total cell lysates were sep-
arated on a 12.5% polyacrylamide gel containing sodium dodecyl-
sulfate (SDS) and transferred onto a methanol-activated polyvinyli-
dene fluoride membrane. The membranes were pre-incubated for
1 h at 4°C in blocking buffer (5% Marvel milk powder in TBS-T; 10
mM Tris-HCl, pH 8.0, 0.15 M NaCl, 0.1% Tween-20) to prevent
non-specific antibody binding.
After blocking, the membranes were incubated overnight at
room temperature with mouse anti-DMα (1:1000; 5C1)25 or β-actin
(1:3000; Chemicon, Billerica, MA, USA) antibody. After four wash-
ing steps with TBS-T, the membranes were incubated for 1 h with
horseradish peroxidase-labeled goat anti-mouse (1:2500; Dako,
Glostrup, Denmark) secondary antibody and protein complexes
were visualized by Amersham ECL Western Blotting Detection
Reagents (GE Healthcare, Buckinghamshire, UK).
Retrovirus production, transductions and drug selection
A pSIREN-RetroQ vector (Clontech) containing a puromycin
resistance gene and a specifically prepared Ii short interfering RNA
(siRNA) insert (sequence 53) was used to silence Ii expression.
Retrovirus production and transduction were performed as
described earlier,18,26 and also stated in the Online Supplementary
Appendix.
After generation of stable Ii siRNA-transduced myeloid leukemic
cells, no differences in cell growth were observed during culture
between these and wild type blasts. As demonstrated in a previous
study,26 the process of retroviral transduction and siRNA formation
does not influence Ii expression and CD4+ T-cell induction.
Allogeneic T-cell proliferation assays
Mixed leukocyte reactions (MLR) were performed in 96-well
round-bottomed plates (Costar) with myeloid leukemic blasts act-
ing as stimulator cells and allogeneic CD4+ T cells as responder
cells. To obtain CD4+ T cells, peripheral blood mononuclear cells
were isolated from buffy coats of different healthy donors by den-
sity gradient centrifugation (Ficoll-Paque; Amersham Biosciences).
Subsequently, cells were negatively selected for CD14 and CD8
with microbeads using magnetic cell separation columns (MACS;
Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of the
resulting CD4+ cell population exceeded 95%, as confirmed by
flow cytometric analysis (data not shown).
Myeloid leukemic blasts were irradiated at 30 Gy and added,
with or without HLA-DR blocking antibody (L243; 11.5 µg/mL), to
a fixed concentration of 1×105 responder cells per well. After co-cul-
turing at different stimulator-to-responder ratios for 5 days, each
well was pulsed with 0.4 mCi [3H]-thymidine (Amersham
Pharmacia Biotech, Buckinghamshire, UK) for 18 h at 37°C in a
humidified 5% CO2 atmosphere. Co-cultures were harvested onto
a fiberglass filter and analyzed for [3H]-thymidine incorporation as
a measure of cell proliferation using a liquid scintillation counter
(Wallac, Turku, Finland).
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Figure 1. Kaplan-Meier curves for disease-free survival of AML
patients. A significant difference was observed between patients
with HLA-DR+CLIP– leukemic blasts and patients with HLA-DR+CLIP+
leukemic blasts, both in the total (panel A; P=0.013, log-rank) and
intermediate cytogenetic risk (panel B; P=0.025, log-rank) groups of
patients. Cut-off levels of 45% of blasts positive for HLA-DR and
35% of blasts positive for CLIP were used.
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Autologous T-cell proliferation assays
CLIP–CD45dim and CLIP+CD45dim myeloid leukemic blasts were
sorted from thawed de novo AML patients’ samples by using a
FACSAria flow cytometer (BD). For this flow cytometric sorting,
cells were stained with the PerCP-labeled CD45 (BD) and PE-labeled
cerCLIP.1 (Santa Cruz Biotechnology) monoclonal antibodies. To
select for CD4+ T cells, we collected peripheral blood from patients
in complete remission for more than 6 months and isolated the
mononuclear fractions as described above. Peripheral blood
mononuclear cells were negatively selected for CD14 and positively
selected for CD4 with microbeads using MACS (Miltenyi Biotec).
Remission CD4+ T cells (5×105) were cultured together with irradiat-
ed blasts from the same patient at a 1:1 ratio in RPMI 1640 medium
(Gibco) containing 10% human AB serum (ICN Biochemicals,
Aurora, OH, USA), 1% penicillin/streptomycin, 50 µM 2-ME and
interleukin-7 (10 ng/mL; Miltenyi Biotec). CD4+ T cells were re-stim-
ulated once a week at least twice with blasts and cultured again in
fresh medium. Interleukin-2 (50 U/mL; Miltenyi Biotec) was added
2 days after each stimulation with blasts. CD4+ T-cell proliferation
was determined by trypan blue dye exclusion. 
Statistical analysis
Statistical analyses were conducted using SPSS 15.0 software. To
determine associations between variables, Spearman’s correlation
coefficient was used. Differences between patients’ characteristics
were analyzed with the Mann-Whitney U test. For survival data,
Kaplan-Meier curves were compared by means of the log-rank test.
Multivariate Cox regression analysis was performed to evaluate the
predictive value of several variables on survival.
Results
High relative amount of CLIP on leukemic blasts 
is correlated with poor clinical outcome
We previously demonstrated that high CLIP expression on
leukemic blasts was correlated with poor clinical outcome in
a cohort of 111 AML patients (1992-2003).22 We have now
expanded this cohort to 207 patients (1992-2007). These
patients’ characteristics are presented in the Online
Supplementary Table S1, showing that the cohort is a represen-
tative group of AML patients.
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Figure 2. Screening of several HLA-DR+
myeloid leukemic cell lines for expression
of proteins involved in HLA class II antigen
presentation. (A) Fluorescence histograms
displaying HLA-DR (DR), CLIP and invariant
chain (Ii) as well as HLA-DM (DM) and HLA-
DO (DO) expression intensities (unfilled
peaks) of KG-1, ME-1, THP-1 and Kasumi-1
blasts with their appropriate isotype con-
trols (gray filled peaks). Flow cytometric
analysis was performed on 7AAD- blasts.
(B) Western blot analysis of DMα (35 kD)
expression in blasts of the THP-1 and
Kasumi-1, compared to the KG-1 cell line.
As a loading control, β-actin (42 kD) was
used.
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CLIP expression in this cohort was comparable to that in
the 1992-2003 cohort and ranged from 1-99% (mean 30.5%,
median 24%). The relative amount of CLIP ranged from
0.0006-5.3 (mean 0.23, median 0.03). As already previously
shown in a smaller subset of patients, both high CLIP expres-
sion and a high relative amount of CLIP were significantly
correlated with a shortened overall survival (P=0.007 and
P=0.027, respectively, Spearman’s correlation). Furthermore,
a cut-off level of 35% for CLIP expression resulted in a signif-
icant difference in Kaplan-Meier survival curves for disease-
free survival of AML patients (Figure 1A; P=0.013, log-rank
test). Multivariate analysis revealed that the relative amount
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THP-1
Kasumi-1
Figure 3. The effect of invari-
ant chain (Ii) silencing in
myeloid leukemic cell lines
on the relative amount of
CLIP. THP-1 and Kasumi-1
blasts were analyzed for the
expression of intracellular Ii
(panel A and C, respectively)
and extracellular HLA-DR
(DR) and CLIP (panel B and
D, respectively) by flow
cytometry. Due to variable
sensitivity for the retroviral
transduction and selection
procedure of THP-1 and
Kasumi-1 blasts, measure-
ments on viable blasts could
not be performed until day
27 and 35, respectively, after
transduction. Absolute MFI
values and relative CLIP
amounts were defined as
described in the Design and
Methods section. As an
example, DR and CLIP levels
of one of two independent Ii
siRNA transductants are
depicted. The M1 and M2
regions indicate the percent-
ages of CLIP+ and DR+ blasts,
respectively. Ii expression
and relative CLIP amounts
represent the means (± SD)
of two independent Ii siRNA
transductants; N/A, not appli-
cable.
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of CLIP is a significant predictor of disease-free survival, in
contrast to white blood cell count and age (P=0.023, P=0.36
and P=0.37, respectively, Cox regression). No significant
association was found between each of the FAB subtypes
and disease-free survival.
As the numbers of patients in the good and poor cytoge-
netic risk groups were too small to enable reliable multivari-
ate analysis, we determined the predictive value of CLIP in
patients with an intermediate cytogenetic risk profile. When
analyzing this intermediate risk patient group, the largest
group in our cohort, again significant differences in survival
curves were found between HLA-DR+CLIP– and HLA-
DR+CLIP+ groups of patients (Figure 1B; P=0.025, log-rank).
In conclusion, in this expanded group of patients, we were
able to confirm that a high relative amount of CLIP on
leukemic blasts predicts a poor clinical outcome for AML
patients, indicating that impaired HLA class II antigen pres-
entation on leukemic blasts is functionally involved in dis-
ease progression.
Immunophenotypic characterization of blasts from myeloid
leukemic cell lines reveals different expression patterns of
proteins involved in the HLA class II presentation pathway
To explore the functional role of HLA class II antigen pres-
entation on leukemic blasts, we screened six myeloid
leukemic cell lines for the expression of the key proteins
involved in the HLA class II presentation pathway by flow
cytometry. Plasma membrane HLA-DR and CLIP as well as
intracellular Ii, HLA-DM and HLA-DO expression levels are
shown for four of these cell lines (Figure 2A). Blasts of the
HL-60 and U-937 AML cell line did not express HLA-DR or
CLIP at all (data not shown).
Strong HLA-DR expression was observed on blasts of both
the KG-1 and ME-1 AML cell lines (mean fluorescence inten-
sity, MFI=199.7 and 96.5, respectively), while no CLIP expres-
sion was detected (group I). The THP-1 and Kasumi-1 AML
cell lines not only expressed high levels of HLA-DR levels
(MFI=47.0 and 34.6, respectively), but also CLIP (MFI=55.7
and 36.2, respectively) was clearly present at the plasma
membrane (group II). Ii was abundantly expressed in the
AML cell lines of both groups, which indicates that the
observed differences in plasma membrane expressed CLIP are
induced by HLA-DM and/or HLA-DO in the MIIC. When
comparing HLA-DM and HLA-DO expression levels between
the AML cell lines of groups I and II, HLA-DM expression was
found in CLIP– KG-1 and ME-1 blasts (MFI=30.8 and 13.6,
respectively), whereas its expression was very low in CLIP+
THP-1 and Kasumi-1 blasts. This low HLA-DM expression in
THP-1 and Kasumi-1 blasts was confirmed by western blot
analysis (Figure 2B). HLA-DO expression was only detected
in 42% of KG-1 blasts (MFI=4.0), while blasts of the other
AML cell lines from group I and II were negative.
In conclusion, these findings demonstrate that, in the AML
cell lines of group I, the presence of HLA-DM (and the rela-
tive absence of HLA-DO expression) probably causes an
exchange of CLIP for antigenic peptides in the MIIC, which
results in a HLA-DR+CLIP– phenotype of blasts. These blasts
presumably have the ability to present leukemia-associated
antigens. In the AML cell lines of group II, regarding the low
amount of HLA-DM, CLIP may poorly dissociate from HLA-
DR in the MIIC, leading to a DR+CLIP+ phenotype with con-
sequent aberrant HLA class II antigen presentation. 
Invariant chain silencing in HLA-DR+CLIP+ THP-1 and
Kasumi-1 blasts contributes to reduced relative amounts
of CLIP at the plasma membrane
Since a high relative amount of HLA-DR molecules occu-
pied by CLIP interferes with antigen presentation, we used Ii
as a target in HLA-DR+CLIP+ THP-1 and Kasumi-1 blasts to
lower the relative amount of CLIP and thereby increase HLA-
DR-mediated antigen presentation at the plasma membrane.
For this purpose, we transduced both cell lines with retro-
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Figure 4. Proliferation assays of allogeneic CD4+ T cells stimulated
with CLIP down-modulated blasts of myeloid leukemic cell lines. The
ability of CLIP+ (wild type) and CLIP– (Ii-silenced) THP-1 blasts (panel
A) and Kasumi-1 blasts (panel B) to induce allogeneic CD4+ T-cell
proliferation was compared in different MLR. CD4+ T cells were
obtained from three independent healthy donors. Stimulator-to-
responder ratios of 1:5, 1:10, 1:20, 1:40 and 1:80 were used togeth-
er with a negative control (only stimulator cells; ‘Neg’). MLR were
carried out in triplicate at each stimulator-to-responder ratio. MLR
with CD4+ T cells from donor 1 were performed twice (donor 1.1 and
1.2) for both cell lines to confirm reproducibility. In each graph, the
days after Ii-siRNA transduction is noted at which Ii-silenced blasts
were tested in the MLR. Results show the means (± SEM) of [3H]-
thymidine incorporation in counts per minute (cpm), as an indicator
of CD4+ T-cell proliferation.
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viruses encoding for specific Ii siRNA and subsequently fol-
lowed intracellular Ii as well as HLA-DR and CLIP expression
at the plasma membrane for 6 weeks of cell culture by using
flow cytometry. Wild type blasts exhibited stable expression
of Ii, HLA-DR and CLIP during this period (data not shown). 
THP-1/Ii-siRNA transductants
Immunofluorescence staining of Ii siRNA-transduced THP-
1 (THP-1/Ii-siRNA) blasts showed a clear reduction in Ii
expression level at day 27 (MFI=2.9) and day 42 (MFI=1.4)
after transduction, compared to that of wild type blasts
(MFI=4.5) (Figure 3A). At the same time points, decreased
amounts of CLIP were observed on THP-1/Ii-siRNA blasts,
as MFI values dropped from 36.2 to 7.8 and 4.2, respectively.
Interestingly, in spite of the strong decline in Ii expression,
HLA-DR levels remained relatively constant at the plasma
membrane (MFI=36.5 and 27.1). Due to these different
effects of Ii silencing on CLIP and HLA-DR expression, the
relative amounts of CLIP on THP-1/Ii-siRNA blasts decreased
from 1.24 to 0.56 (±0.03) and 0.42 (±0.06), respectively
(Figure 3B).
Kasumi-1/Ii-siRNA transductants
Similar Ii expression decreases were noted in Ii-siRNA-
transduced Kasumi-1 (Kasumi-1/Ii-siRNA) blasts, with MFI
values declining from 13.5 to 2.2 at day 35 and 0.9 at day 42
after transduction (Figure 3C). In contrast to THP-1/IisiRNA
blasts, Kasumi-1/Ii-siRNA blasts not only displayed reduced
amounts of CLIP (MFI dropped from 35.5 to, respectively, 3.0
and 1.1), but HLA-DR expression was also markedly influ-
enced (MFI dropped from 24.6 to, respectively, 4.1 and 1.0).
Still, a stronger decline was observed in expression levels of
CLIP compared to those of HLA-DR at day 35 after transduc-
tion, which resulted in a decrease of the relative amount of
CLIP from 1.5 to 0.8 (±0.09) (Figure 3D). At day 42 after
transduction, HLA-DR expression levels on Kasumi-1/Ii-
siRNA blasts were too low to determine the relative amount
of CLIP. These data reveal that Ii silencing with specific
siRNA affects HLA-DR expression differently in THP-1 and
Kasumi-1 blasts. However, relative amounts of CLIP were
strongly decreased at the plasma membrane, which may
cause altered HLA class II antigen presentation, either stable
or transient, on Ii-silenced blasts of both cell lines.
Reduced relative CLIP amounts on invariant chain-silenced
THP-1 and Kasumi-1 blasts increases their ability to
induce allogeneic CD4+ T-cell proliferation 
To assess the functional impact of CLIP variation, we test-
ed Ii-silenced THP-1 and Kasumi-1 blasts with reduced rela-
tive amounts of CLIP for their ability to induce allogeneic
CD4+ T cells as compared to wild type blasts. We isolated
CD4+ T cells from three different healthy donors and ana-
lyzed their proliferative responses to these blasts in MLR at
various stimulator-to-responder ratios.
THP-1/Ii-siRNA transductants
MLR performed with THP-1/Ii-siRNA blasts (day 42)
revealed strong increases in proliferation of CD4+ T cells from
donor 1, in a dose-dependent manner (as shown in Figure
4A). This was in agreement with the decrease in relative
amount of CLIP on THP-1/Ii-siRNA blasts at day 42 after
transduction (Figure 3B). On the other hand, low proliferative
responses were noted in MLR with THP-1 wild type blasts
and CD4+ T cells obtained from the same donor. This result-
ed in a maximum mean increase in CD4+ T-cell proliferation
of 4.5 (±1.0)-fold when comparing the two experiments of
THP-1/Ii-siRNA blasts to those of THP-1 wild type blasts
(Figure 4A). Although mild alloreactivity of CD4+ T cells from
donors 2 and 3 was observed against THP-1 wild type blasts,
their reactivity against THP-1/Ii-siRNA blasts was increased
much more at the highest stimulator-to-responder ratios
(Figure 4A). Importantly, the induction of CD4+ T-cell prolif-
eration by THP-1/Ii-siRNA blasts was prevented in the pres-
ence of the HLA-DR blocking monoclonal antibody L243,
which confirmed HLA-DR restriction of these proliferative
responses in MLR. 
Kasumi-1/Ii-siRNA transductants
In accordance with the MLR with THP-1/Ii-siRNA blasts
(day 42), MLR performed with Kasumi-1/Ii-siRNA blasts
(day 35) showed high proliferative responses of CD4+ T cells
from donor 1, also in a dose-dependent manner (Figure 4B).
When compared to MLR with Kasumi-1 wild type blasts, a
5.1-fold increase in CD4+ T-cell proliferation was found at the
highest stimulator-to-responder ratio. However, in MLR per-
formed with Kasumi-1/Ii-siRNA blasts at day 54 after trans-
duction, no proliferation was observed of CD4+ T cells
obtained from the same donor. When Kasumi-1/IisiRNA
blasts at day 35 after transduction were co-cultured in MLR
with CD4+ T cells from donor 3, strong increases with
respect to CD4+ T-cell proliferation were observed again, as
compared to wild type blasts (Figure 4B). In addition, MLR
between Kasumi-1/Ii-siRNA blasts (day 52) and CD4+ T cells
from donor 2 showed no induction of proliferation (Figure
4B), in contrast to THP-1/Ii-siRNA blasts (day 33) and CD4+
T cells from the same donor (Figure 4A). These results were
in line with the total absence of HLA-DR expression
observed on Kasumi-1/Ii-siRNA blasts at day 42 after trans-
duction (Figure 3D).
Overall, in contrast to wild type blasts, Ii-silenced THP-1
and Kasumi-1 blasts that retained their HLA-DR expression
were able to induce marked allogeneic CD4+ T-cell responses
in a HLA-DR-restricted manner, indicating that a reduced rel-
ative amount of CLIP on myeloid leukemic blasts leads to an
enhancement of tumor immunogenicity.
CLIP– leukemic blasts derived from patients with acute
myeloid leukemia are able to stimulate autologous 
remission CD4+ T cells in contrast to CLIP+ leukemic blasts
We further evaluated the role of a low relative amount of
CLIP in tumor immunogenicity by using primary leukemic
blasts of HLA-DR+ AML patients and CD4+ T cells isolated
from the same patients in complete remission. CLIP– and
CLIP+ leukemic blasts were flow cytometrically sorted from
AML patients’ samples and cultured with autologous remis-
sion CD4+ T cells several times during culture. For two differ-
ent AML patients, we found a strong increase in proliferation
rate of CD4+ T cells that were stimulated with CLIP–-sorted
blasts (Online Supplementary Figure S1). CD4+ T cells from
patient 1 already showed high proliferative responses at day
12 (after one re-stimulation) and the proliferation of CD4+ T
cells from patient 2 markedly increased at day 28 (after three
re-stimulations). No increase in proliferation was observed
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with CD4+ T cells that were equally stimulated with CLIP+-
sorted blasts from the same patient. Pre-treatment of CLIP–-
sorted blasts with the HLA-DR blocking monoclonal anti-
body L243 abolished the blasts’ ability to induce CD4+ T-cell
proliferation, indicating that the increase in proliferation was
restricted to HLA-DR expression on these blasts.
From these experiments we conclude that the absence of
CLIP on leukemic blasts of AML patients results in increased
recognition by autologous remission CD4+ T cells, which
may imply that the relative amount of CLIP is a critical fac-
tor for the immunogenicity of leukemic blasts.
Discussion
The ultimate goal in cancer immunotherapy is to generate
effective and long-lasting immune responses against tumor
cells in vivo. In AML, leukemic blasts might have specific
characteristics that allow them to escape immune surveil-
lance. We previously showed that increased HLA class II-
mediated antigen presentation of the self-peptide CLIP on
leukemic blasts from AML patients is significantly associated
with a poor clinical outcome.22 Statistical analysis on an
expanded cohort of newly diagnosed AML patients (n=207)
confirmed our finding by showing that the relative amount
of CLIP on leukemic blasts is a strong predictor of disease-
free survival (Figure 1A). This underlines our hypothesis that
the presence of CLIP on leukemic blasts acts as an important
immune escape mechanism in these patients after achieving
complete remission. It has already become clear that the use
of modulated leukemic blasts as APC is an emerging
approach to activate the immune system in AML patients.27,28
It is, therefore, a challenge to develop immunotherapeutic
strategies that down-modulate the relative amount of CLIP
on leukemic blasts, resulting in enhanced HLA class II antigen
presentation and immune recognition.
Immunophenotypic screening of several human myeloid
leukemic cell lines revealed large differences in relative
amounts of CLIP (Figure 2A), which is in line with the results
from a study performed by Harris et al.29 CLIP– KG-1 and ME-
1 blasts abundantly expressed HLA-DM while CLIP+ THP-1
and Kasumi-1 blasts did not (Figure 2A-B), indicating that the
catalytic function of HLA-DM is important for HLA-DR-
restricted peptide loading in these cell lines. This agrees with
the association between CLIP/HLA-DR and HLA-DO/HLA-
DM expression that was found previously for B cells,30 as
well as leukemic blasts.22 We observed low levels of HLA-DO
expression in the HLA-DMlow THP-1 and Kasumi-1 cell lines
(Figure 2A), which contrasts with the high levels of expres-
sion that were recently demonstrated in two other HLA-
DMlow leukemic cell lines, the HL-60 and K562.31 The HLA-
DMlowHLA-DO– immunophenotype of the THP-1 and
Kasumi-1 cells implies an acquired ineffectiveness of blasts to
regulate HLA-DR-restricted peptide loading in the MIIC. Our
data on the expression patterns for KG-1 (early myeloblast;
CLIP–HLA-DM+HLA-DO+), ME-1 (myelomonocyte with
eosinophilia; CLIP–HLA-DM+HLA-DO–), THP-1 (monocyte;
CLIP+HLA-DMlowHLA-DO–) and Kasumi-1 (late myeloblast;
CLIP+HLA-DMlowHLA-DO–) blasts further indicates a poten-
tial relationship with the degree of maturation. We hypothe-
size that, during differentiation, the ability of myeloid blasts
to regulate HLA-DR-restricted peptide loading in the MIIC is
impaired and, hence, CLIP expression at the plasma mem-
brane is increased. This contrasts with the proposal by Harris
et al. that exogenous antigen processing is a developmentally
acquired characteristic for myeloid blasts.29
Despite the similar immunophenotype of THP-1 and
Kasumi-1 blasts (Figure 2), Ii silencing had different effects on
surface expression of HLA-DR (Figure 3B, D). According to
the conventional pathway of HLA class II antigen presenta-
tion, Ii is required for the transport of HLA class II molecules
from the endoplasmic reticulum to the MIIC. In monocytic
THP-1 blasts however, we found that upon silencing of Ii,
HLA-DR molecules were still able to be expressed extracellu-
larly. As Ii also prevents binding of endogenous peptides to
newly synthesized HLA class II molecules in the endoplas-
mic reticulum,32 this might indicate that HLA-DR molecules
in THP-1/Ii-siRNA blasts are loaded with endogenous pep-
tides, including leukemia-associated peptides, thereby
bypassing the Ii-dependent routing to the MIIC. This is in
agreement with the ability of monocyte-derived dendritic
cells to present endogenous antigens to CD4+ T cells.33 On the
other hand, Kasumi-1/Ii-siRNA blasts exhibited strongly
reduced levels of extracellular HLA-DR, resulting in a
decrease of the blasts’ capacity to stimulate allogeneic CD4+
T cells. Nevertheless, during the Ii silencing process, a clear
decrease in relative amount of CLIP was observed at day 35
after transduction (Figure 3D), which may allow an altered,
although transient, HLA-DR-mediated antigen presentation
around these time points. These results may imply a differ-
ence in Ii dependency of HLA-DR-mediated antigen presen-
tation between blasts from the monocytic lineage (THP-1)
and the granulocytic lineage (Kasumi-1) of myeloid differen-
tiation.
We further demonstrated that a low relative amount of
CLIP on leukemic blasts resulted in increased CD4+ T-cell
induction, both in allogeneic and autologous settings. THP-
1/Ii-siRNA and Kasumi-1/Ii-siRNA blasts (35 days after trans-
duction) were found to strongly induce allogeneic CD4+ T-
cell proliferation (Figure 4A-B), in a manner inversely corre-
lated to their relative amounts of CLIP. These observations
are in agreement with those of previous studies, in which it
was shown that HLA class II+ tumor cells lacking Ii expres-
sion were able to enhance tumor-reactive CD4+ T-cell activa-
tion.18,19 In MLR performed with CD4+ T cells from donors 2
and 3, some alloreactivity was observed against THP-1 and
Kasumi-1 wild type blasts. The allogeneic CD4+ T-cell
responses to both THP-1/Ii-siRNA and Kasumi-1/Ii-siRNA
blasts at day 35 after transduction were, however, much
higher, indicating that these responses were, at least partly,
peptide-specific.
Recent studies show that alloreactive T cells can indeed
specifically react against HLA-peptide ligands.34 In addition,
CLIP– leukemic blasts from AML patients were also able to
stimulate proliferation of autologous remission CD4+ T cells,
in contrast to CLIP+ leukemic blasts (Online Supplementary
Figure S1). As a low relative amount of CLIP is likely related
to increased tumor peptide presentation, this increase in
CD4+ T-cell induction might functionally explain the
improved clinical outcome of AML patients with less than
35% of leukemic blasts expressing CLIP (Figure 1).
Taken together, our study demonstrates that CLIP expres-
sion on myeloid leukemic blasts affects the blasts’ recogni-
tion by CD4+ T cells and could be a mechanism for escaping
from immune surveillance. We hypothesize that leukemic
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blasts with a HLA-DR+CLIP– phenotype at their plasma
membrane are able to present endogenous antigens by HLA-
DR, thereby evoking CD4+ T-cell induction as observed in
our proliferation assays. Since the immunological escape of
leukemic blasts is a major obstacle to the development of
immunotherapy in AML, molecular interventions that down-
modulate the relative amount of CLIP might be used as an
additional strategy in AML dendritic cell and whole-cell vac-
cination protocols to activate leukemia-specific CD4+ T cells.
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